公开(公告)号：US20060009452A1

公开(公告)日：2006-01-12

申请号：US11143707

申请日：2005-06-03

申请人： Sergei Atamas ,  Irina Luzina ,  Barbara White

发明人： Sergei Atamas ,  Irina Luzina ,  Barbara White

IPC分类号： A61K31/5377

CPC分类号： C07K14/523 ,  A61K31/5377 ,  C07K14/7158

摘要： The present invention relates to methods of treating, preventing or preventing the progression of fibrosis comprising inhibiting the actions of pulmonary and activation-regulated chemokine (PARC) or at least one of its downstream effector molecules, such as Sp1 transcription factor and protein kinase C-alpha (PKCα). The present invention also relates to methods of screening and/or identifying compounds useful for the treatment of fibrosis comprising contacting PARC or its downstream effector molecules, such as Sp1 or PKCα, with a substance and subsequently determining the effects of the substance on the activity of PARC or Sp1 or PKCα. The present invention also relates to methods of screening and/or identifying compounds that prevent or inhibit collagen deposition comprising contacting PARC or its downstream effector molecules, such as Sp1 or PKCα, with a substance and subsequently determining the effects of the substance on the activity of PARC or Sp1 or PKCα.

摘要翻译： 本发明涉及治疗，预防或预防纤维化进展的方法，包括抑制肺和活化调节的趋化因子（PARC）或其至少一种下游效应分子如Sp1转录因子和蛋白激酶C- α（PKCalpha）。 本发明还涉及筛选和/或鉴定可用于治疗纤维化的化合物的方法，包括将PARC或其下游效应分子如Sp1或PKCα与物质接触，随后确定物质对活性的影响 PARC或Sp1或PKCalpha。 本发明还涉及筛选和/或鉴定预防或抑制胶原蛋白沉积的化合物的方法，其包括将PARC或其下游效应分子如Sp1或PKCα与物质接触，随后确定物质对活性的影响 PARC或Sp1或PKCalpha。

公开(公告)号：US20090124570A1

公开(公告)日：2009-05-14

申请号：US12261113

申请日：2008-10-30

申请人： Sergei P. Atamas ,  Irina Luzina

发明人： Sergei P. Atamas ,  Irina Luzina

IPC分类号： A61K31/7105

CPC分类号： A61K31/7105 ,  C12N5/0645 ,  C12N5/0656 ,  C12N2501/15 ,  C12N2502/1323

摘要： Compositions and methods for facilitating tissue repair by enhancing the actions of BIGH3 or at least one of its downstream effector molecules in injured tissue, and for the diagnosis, prophylactic and therapeutic treatment of fibrosis by inhibiting the actions of BIGH3 or at least one of its downstream effector molecules, such as PU.1 transcription factor and MMP14. Other disclosed methods include methods of screening and/or identifying compounds useful for facilitating tissue repair, treating fibrosis, or for altering the accumulation or deposition of collagen, comprising contacting BIGH3 or its downstream effector molecules, such as PU.1 or MMP14, with a substance and subsequently determining the effects of the substance on the activity of BIGH3, PU.1, or MMP14.

摘要翻译： 通过增强BIGH3或其受损组织中的至少一个下游效应分子的作用促进组织修复的组合物和方法，以及通过抑制BIGH3或其下游的至少一个的作用来诊断，预防和治疗纤维化 效应分子，如PU.1转录因子和MMP14。 其他公开的方法包括筛选和/或鉴定可用于促进组织修复，治疗纤维化或改变胶原蛋白积聚或沉积的化合物的方法，包括将BIGH3或其下游效应分子例如PU.1或MMP14与 物质并随后确定该物质对BIGH3，PU.1或MMP14活性的影响。